Based on the promising results in these studies, 153Sm-EDTMP has several potential applications in the treatment of hematologic malignancies: single-agent activity in myeloma for management of pain and possible M-protein response, combinatorial use in myeloma with bortezomib or other radiosensitizing chemotherapy and high-dose 153Sm-EDTMP as a component of pre-transplant conditioning regimens for a variety of malignancies. This evidence concerns the gene MYOM2 and plasma cell myeloma.